Beta-amyloid is a small protein fragment that forms naturally in the brain throughout your life. It’s produced when a larger protein embedded in brain cell membranes gets cut into smaller pieces by enzymes. In healthy brains, beta-amyloid is made and cleared away routinely. The protein became famous because when it accumulates and clumps together, it forms the sticky plaques found in the brains of people with Alzheimer’s disease.
How Beta-Amyloid Is Made
Your brain cells contain a large protein called amyloid precursor protein, or APP, that sits in the outer membrane of neurons. Think of it as a long chain threaded through the cell wall. Two enzymes act like molecular scissors, cutting APP at specific points to release the beta-amyloid fragment.
The first cut comes from an enzyme called beta-secretase, which snips the outer portion of APP. This leaves a short stub still anchored in the membrane. A second enzyme, gamma-secretase, then cuts that stub, releasing the beta-amyloid piece into the space between cells. The exact spot where gamma-secretase cuts determines the length of the fragment. Most pieces are 40 amino acids long, but some are 42 amino acids long, and that slightly longer version is stickier and more prone to clumping.
There’s also a competing pathway. A different enzyme, alpha-secretase, can cut APP right through the middle of the beta-amyloid region, effectively preventing the fragment from ever forming. In a healthy brain, this protective pathway handles a significant share of APP processing.
What Beta-Amyloid Does in a Healthy Brain
For decades, scientists treated beta-amyloid as purely harmful, a waste product with no purpose. That view has shifted. Emerging evidence suggests that at low concentrations, the protein actually serves several useful functions. It appears to help fight microbial infections, acting as a natural antimicrobial agent. It plays a role in regulating synaptic plasticity, the process by which brain connections strengthen or weaken during learning and memory. Research also points to roles in promoting recovery after brain injury and helping seal leaks in the blood-brain barrier.
The key concept is dose. At normal, low levels beta-amyloid appears neuroprotective. At high concentrations, it becomes toxic. This pattern, where a substance is beneficial in small amounts and harmful in large ones, explains why simply eliminating all beta-amyloid isn’t a straightforward solution.
How It Becomes Harmful
Problems start when beta-amyloid production outpaces the brain’s ability to clear it, or when the clearance machinery slows down with age. Individual beta-amyloid molecules begin sticking to each other. First they form small clusters called oligomers (just a handful of molecules), then larger clumps called fibrils, and eventually the dense, insoluble deposits visible under a microscope as amyloid plaques.
For years, scientists assumed the large plaques were the primary villains. That thinking has been revised. Studies show that the small, soluble oligomers kill roughly three times more brain cells than the larger fibril deposits at equivalent concentrations. Mathematical modeling suggests the size difference alone could account for up to a tenfold gap in toxicity, because smaller particles have more surface area exposed to interact with neurons. The plaques may actually serve as a reservoir, slowly releasing toxic oligomers into surrounding tissue rather than doing most of the damage themselves.
These oligomers disrupt communication between neurons, trigger inflammatory responses, and eventually cause cells to die. This progressive damage is closely associated with the memory loss and cognitive decline seen in Alzheimer’s disease.
The Amyloid Hypothesis and Its Limits
The “amyloid hypothesis,” the idea that beta-amyloid buildup is the central trigger of Alzheimer’s, has dominated research for over 30 years. It’s supported by strong genetic evidence: people with inherited mutations that increase beta-amyloid production develop Alzheimer’s at unusually young ages. And removing amyloid plaques with new drugs does slow cognitive decline modestly.
But the hypothesis has significant gaps. Mice engineered to develop amyloid plaques frequently show only mild cognitive problems and often don’t lose many neurons, a hallmark of human Alzheimer’s. Some older adults have brains full of plaques at autopsy yet never showed signs of dementia during life. And over the past 15 years, dozens of drugs targeting amyloid failed in clinical trials, suggesting the picture is more complicated than one protein gone wrong.
Growing evidence points to a web of interacting factors: chronic brain inflammation, disruptions in the gut-brain connection, environmental toxicants, metabolic dysfunction, and aging itself. Many researchers now view beta-amyloid buildup as one important piece of a larger puzzle rather than the sole cause of Alzheimer’s.
How Amyloid Buildup Is Detected
Amyloid accumulation can now be measured in living people through two main methods. The first is a PET brain scan using a radioactive tracer that binds to amyloid plaques. On a negative (normal) scan, the tracer highlights only the brain’s white matter, and you can clearly see the grooves between brain folds. On a positive scan, the tracer spreads into the cortex, blurring those grooves. The outer surface of the brain appears outlined rather than showing its normal folded pattern, and the gap between the two hemispheres may become thin or disappear. The buildup tends to be symmetrical and concentrates in the lateral temporal and frontal lobes, along with an area deep in the midline called the precuneus, while regions controlling movement and vision are often spared.
The second method is a blood test, which is newer and far less expensive than a PET scan. Tests measuring a specific form of a protein called p-tau217, either alone or combined with another blood marker, have shown remarkable accuracy. In clinical studies, these blood tests correctly identified people with amyloid-positive PET scans with about 95% sensitivity and 95% specificity. That performance is essentially equivalent to the traditional method of testing spinal fluid, which requires a lumbar puncture. The availability of a simple blood draw is expected to dramatically change how early Alzheimer’s screening works in routine medical practice.
Treatments That Target Amyloid
The first drugs designed to directly remove beta-amyloid plaques from the brain reached the market recently. These are antibody infusions given intravenously that bind to amyloid and help the immune system clear it.
Lecanemab, approved under the brand name Leqembi, reduced amyloid plaque levels by about 59 centiloids (a standardized measure of plaque density) over 18 months in clinical trials, bringing many patients from clearly abnormal levels down near the threshold for normal. It slowed the rate of cognitive decline by 27% compared to placebo. That translates to a modest but measurable difference in day-to-day functioning.
Donanemab, sold as Kisunla and approved in 2024, showed even more dramatic plaque clearance. Patients’ amyloid levels dropped by roughly 88 centiloids on average, and about 80% of treated patients achieved complete clearance of amyloid plaques on PET scans. Cognitive decline slowed by approximately 35% on one measure and 40% on another. A third drug, aducanumab, was approved earlier but withdrawn from the market in 2024 due to limited uptake and ongoing debate about whether its benefits justified its risks.
These results confirmed that amyloid removal is possible and does affect the course of disease, but the clinical benefits remain modest. Patients still decline, just more slowly. This reinforces the idea that amyloid is a real contributor to Alzheimer’s progression, but clearing it alone isn’t enough to stop the disease. Both approved treatments also carry a risk of brain swelling or small brain bleeds, side effects that require regular MRI monitoring during treatment.